title: [Clinical research on combined chemotherapy of vinorelbine and cisplatin in the treatment of non-small cell lung cancer].
abstract: BACKGROUND
  To evaluate the efficacy, side-effects, median survival duration and survival rate of vinorelbine (NVB) combined with cisplatin (DDP) in the treatment of non-small cell lung cancer (NSCLC).
  
  
  METHODS
  A total of 220 patients with inoperable NSCLC received NVB and DDP combined chemotherapy: NVB 25-30 mg/(m²*d) on days 1 and 5 (or 8), DDP 60-80 mg/(m²*d) on day 2. The schedule was repeated every 28 days. The efficacy and side-effects were analysed and followed-up after at least two cycles of chemotherapy.
  
  
  RESULTS
  The overall response rate (CR+PR) was 30.9% (68/220). The response rate was 31.3% (51/163) in initial treatment group, and 29.8% (17/57) in retreatment group. The median survival duration was 8.3 months. The 1-, 2- and 3-year survival rates were 39.23%, 19.31% and 6.32%, respectively. The main side-effects were myelosuppression and digestive tract reactions.
  
  
  CONCLUSIONS
  Vinorelbine plus cisplatin is an effective and well-tolerated regimen for non small cell lung cancer and myelosuppression is its dose-limiting toxicity.
authors.affiliation: Department of Medical Oncology, Beijing Tuberculosis & Thoracic Tumor Hospital, Beijing 101149, P.R.China.
authors.forename: Liyan
authors.initials: L
authors.lastname: Xu
authors.forename: Yunzhong
authors.initials: Y
authors.lastname: Zhu
authors.forename: Yonghong
authors.initials: Y
authors.lastname: You
authors.forename: Heling
authors.initials: H
authors.lastname: Shi
authors.forename: Zhe
authors.initials: Z
authors.lastname: Liu
authors.forename: Junfang
authors.initials: J
authors.lastname: Tang
authors.forename: Xinyong
authors.initials: X
authors.lastname: Zhang
authors.forename: Qiyi
authors.initials: Q
authors.lastname: Meng
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Wu
authors.forename: Lili
authors.initials: L
authors.lastname: Guo